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AbsTrACT
Objectives alterations in dopamine neurotransmission 
underlie some of the clinical features of huntington’s 
disease (hD) and as such are a target for therapeutic 
intervention, especially for the treatment of chorea and 
some behavioural problems. however, justification for 
such an intervention is mainly based on case reports and 
small open label studies and the effects these drugs have 
on cognition in hD remain unclear.
Methods in this study, we used the enroll- hD 
observational database to assess the effects of 
antidopaminergic medication on motor, psychiatric 
and cognitive decline, over a 3- year period. We first 
looked at the annual rate of decline of a group of hD 
patients taking antidopaminergic medication (n=466) 
compared with an untreated matched group (n=466). 
The groups were matched on specified clinical variables 
using propensity score matching. next, we studied a 
separate group of hD patients who were prescribed such 
medications part way through the study (n=90) and 
compared their rate of change before and after the drugs 
were introduced and compared this to a matched control 
group.
results We found that hD patients taking 
antidopaminergic medication had a slower progression 
in chorea and irritability compared with those not taking 
such medications. however, this same group of patients 
also displayed significantly greater rate of decline in a 
range of cognitive tasks.
Conclusion in conclusion we found that 
antidopaminergic treatment is associated with 
improvements in the choreic movements and irritability 
of hD but worsens cognition. however, further research 
is required to prospectively investigate this and whether 
these are causally linked, ideally in a double- blind 
placebo- controlled trial.
INTrOduCTION
Huntington’s disease (HD) is an autosomal domi-
nant neurodegenerative disorder caused by an 
expanded CAG (cytosine- adenine- guanine) repeat 
in the HTT gene (mHTT) on chromosome 4. Invol-
untary movements are a classical feature of HD 
although cognitive and psychiatric impairments 
along with other neurological changes are also a 
prominent early feature of the disease and place 
significant burden on patients and their families. 
Cognitive deficits include a loss of higher- order 
‘executive functions’ such as attention, planning, 
flexibility and memory,1 2 as well as compromised 
emotional processing3 and visuospatial perception.1 
In more advanced stages an overall cognitive decline 
is observed leading to dementia in the majority of 
patients. Psychiatric impairments including irri-
tability, obsessive and perseverative behaviours, 
apathy and depression4–6 are evident at all stages of 
the disease.7 8
HD is defined pathologically by the dysfunction 
and subsequent loss of neurons, most notably, in 
early stage disease, in the striatum and cortex9 10—
areas which receive a significant dopaminergic 
input.11 Paradoxically, while there is an early loss of 
postsynaptic dopamine (DA) receptors at these sites, 
one of the most effective and widely used therapies 
involves DA blocking/depleting agents especially 
for chorea.6 However, the empirical evidence for 
this approach is lacking. Only tetrabenazine has 
been subjected to formal efficacy trials, and its use 
is associated with an increased risk of depression 
and anxiety.12
It is well known that in addition to its role in 
motor function, DA is also critical for higher- order 
cognitive processes, in particular executive func-
tion13 as well as psychiatric symptomatology such 
as psychosis, motivating effortful behaviour, rein-
forcement learning and reward processing.14 15 
Regarding cognitive function, it has been postulated 
that DA modulates this in an inverted U function 
fashion, whereby both excessive and insufficient 
cortical levels perturb performance.16 Therefore, 
aberrant DA signalling may also contribute to the 
cognitive disturbances in HD, although this has not 
been well studied.17 It is thus possible that antido-
paminergic treatment targeted at the motor impair-
ments of HD also has an impact on non- motor 
features of the disease.
We therefore sought to investigate the effect of 
antidopaminergic medication on motor, cognitive 
and psychiatric decline in HD using the Enroll- HD 
database. We found that the introduction of these 
medications was associated with improvements in 
chorea and irritability but a decline in cognition.
MeThOds
In this study, data were analysed from the CHDI 
Foundation Enroll- HD study (https://www. enroll- 
hd. org). Enroll- HD is a longitudinal, observational, 
multinational study of HD gene carriers who 
undergo an annual appointment which includes 
a review of current medication and a battery of 
motor, cognitive and psychiatric assessments. Our 
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Table 1 List of antidopaminergic medication included in this analysis
drug
Number of patients on each drug
Group 1 (n=466*) Group 2 (n=90*)
On two or more of the below 175 53
Tetrabenazine 188 28
Sulpiride 34 16
Haloperidol 66 19
Olanzapine 156 49
Tiapride 118 27
Risperidone 98 51
Quetiapine 45 8
Group 1: patients on antidopaminergic medication throughout the study. Group 2: 
patients started on antidopaminergic medications part way through the study.
*Some patients were on more than one of the drugs.
analysis was performed on the fourth data cut comprising 15 
302 participants with an average of 2.4 visits (ranging from 
1 to 6 visits). In the study, motor features are scored using 
the Unified Huntington Disease Rating Scale (UHDRS ’99; 
Huntington Study Group, 1996). Psychiatric features are 
assessed using the problems behavioural assessment (PBA) and 
the depression, irritability and apathy sub- scores from this were 
used in this study. Cognitive assessments include the symbol 
digit modalities test (SDMT), phonemic verbal fluency, Stroop 
and trail making tasks.18 In this paper, we assign a composite 
‘total cognitive score’ for each individual by transforming the 
raw scores for each cognitive task into z- scores (z = (x – μ) 
/ σ) and adding them together to create a single z- score per 
patient. When calculating z- scores, the two groups (antidopa-
minergic medication takers and non- antidopaminergic medi-
cation takers, outlined in detail below) were pooled together 
in order to calculate the population mean and SD. Results for 
individual cognitive task scores are found in the online supple-
mentary section.
data analysis
The data were filtered to include only manifest HD patients, over 
the age of 18, with a CAG repeat length of 36–55 (n=8004). 
Participants with at least two complete visits (n=5011) were 
sorted into two groups, those taking antidopaminergic medica-
tion during the period of data collection (n=2369), and those 
not taking antidopaminergic medication for the entire period 
(n=2642). Next, propensity score matching was performed, 
whereby the two groups were matched for age, CAG repeat 
length, total functional capacity (TFC) score and time since 
diagnosis using the ‘match it’ plugin for R statistical software. 
The ‘nearest neighbour’ matching command was used, which 
selected the most closely matched control for each participant 
in the antidopaminergic medication group (n=466 per group).
We also investigated whether those starting antidopaminergic 
medication part way through the study exhibited changes in the 
rate of motor, cognitive and psychiatric decline following medi-
cation introduction. Individuals with at least two visits prior to 
taking antidopaminergic medication and two visits while taking 
the medication (n=90) were included. Again, we used propen-
sity score matching to match these individuals with a clinically 
comparable control group to give an indication of the average 
change in score for each assessment over the same 4- year period. 
Table 1 outlines the antidopaminergic medications included in 
the analysis.
statistical analysis
Baseline demographics between treatment and control groups 
were compared using t- tests. For multivariate analyses, para-
metric methods were used due to there being a sufficiently large 
sample size. The annual change in score for each assessment 
was calculated for every patient and their average score for each 
assessment across visits was taken. The point change in cogni-
tive, motor or psychiatric performance for each participant was 
calculated by subtracting the first assessment score from the last 
assessment score. A patient’s average score for each assessment 
across visits was then taken.
Group 1: HD antidopaminergic takers (n= 466) and HD controls 
(non-antidopaminergic takers) (n= 466)
For each assessment, the average rate of change of the two 
groups was compared using a univariate ANOVA with change in 
score as the dependent variable, group (antidopaminergic medi-
cation takers vs non- antidopaminergic medication takers) as the 
independent variable and age, CAG repeat length and gender 
as covariates. The resulting p- values were then corrected for 
multiple comparisons (and the associated risk of type 1 errors), 
using the false discovery rate method, with a threshold set at 5% 
(q<0.05). To assess which factors predict the annual change in 
composite cognitive score, a multivariate linear regression was 
used with the addition of the following variables: group, CAG 
repeat length, gender, age, disease burden score (DBS), TFC 
score, time since diagnosis, UHDRS motor score, depression, 
apathy and irritability scores. Psychiatric measures were included 
as they can affect cognitive abilities, likely due to a variety of 
factors including anhedonia, decreased motivation, concentra-
tion difficulties and impairments in attention and processing 
speed.19
In addition to using propensity score matching, we verified 
our results using covariate adjustment, based on the findings 
by Elze et al,20 which showed that this more conventional tech-
nique may be the most reliable method for the analysis of obser-
vational databases. To do this, we compared the yearly rate of 
change between the group taking antidopaminergic medication 
(n=2369) and the group of non- takers (n=2642) using a univar-
iate analysis of variance (ANOVA) with the following covariate 
variables: age, gender, CAG repeat length, DBS, TFC and time 
since diagnosis (see online supplementary section). DBS = (CAG 
– 35.5)*age.21
Group 2: HD pre-antidopaminergic and post-antidopaminergic 
takers (n= 90) and HD controls (non-antidopaminergic takers) (n= 
104)
These patients had completed four annual assessments, the 
antidopaminergic subgroup being on medication for the last 
two assessments only. The rate of change between the first and 
second year (referred to as time interval 1) was compared with 
the rate of change between the third and fourth years (time 
interval 2), using paired t- tests, for both groups separately. Then, 
for each time interval, the rate of decline of the two groups was 
compared with a univariate ANOVA with change in score as the 
dependent variable, group as the independent variable and age, 
CAG repeat length and gender as covariates. Graphpad Prism 
software and IBM SPSS statistics V.25 were used to conduct the 
statistical analysis
resulTs
Of the 5011 manifest HD patients included in our analysis, 
2369 (42%) were taking antidopaminergic medication. These 
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Table 2 Group 1. demographics of participant groups at the first 
appointment, showing the mean with SD in brackets and range below
hd controls (non- 
antidopaminergic takers)
(n=466)
hd antidopaminergic 
takers
(n=466)
Number of visits 3 (1)
2–6
3.1 (1)
2–6
Gender (m:f) 234:232 267:200
ISCED
(educational level)
3.6 (1.2)
1–6
3.5 (1.2)
1–6
Age
(years)
54.6 (9.7)
26–79
54.4 (9.2)
26–79
CAG repeat length 43 (2.1)
40–55
43.1 (2.1)
40–55
DBS 394.4 (55)
180–573.5
397 (55.2)
180–573.5
TFC score 9.9 (2.4)
3–13
9.3 (2.5)
3–13
Time since diagnosis
(years)
3.4 (3.7)
0–22
3.8 (3.7)
0–22
Total motor score UHDRS
Max score 124
28.1 (14.6)
0–81
33.8* (15.5)
0–85
Total chorea score UHDRS
Max score 28
8.2 (4.5)
0–26
9.3* (5.2)
0–28
Irritability
(PBA)
Max score 32
2.5 (3.9)
0–25
3.5* (5.1)
0–28
Depression
(PBA)
Max score 48
4.3 (5.8)
0–36
5.7* (6.7)
0–36
Apathy
(PBA)
Max score 16
2.2 (3.4)
0–16
3.7* (4.4)
0–16
MMSE
Max score 30
26.7 (2.7)
14–30
25.7* (3.3)
11–30
Composite cognitive z- score 1.3 (5.3)
−21.7 to 18.9
 ► 1.3 (5.8)
 ► 32.4–16.7
ISCED, The International Standard Classification of Education; CAG, cytosine- adenine- guanine; MMSE, 
Mini- Mental State Examination.
*Indicates a significant difference (p<0.001) when compared with the control non- antidopaminergic 
medication group.
DBS, disease burden score; HD, Huntington’s disease; PBA, problems behavioural assessment; TFC, total 
functional capacity; UHDRS, Unified Huntington Disease Rating Scale.
Table 3 Group 2. baseline demographics of participants having two 
assessments prior to and two assessments subsequent to starting 
antidopaminergic medication and matched controls, showing the mean 
with SD in brackets
Control group (those not 
taking dopamine medication 
but assessed at the same 
time points)
(n=104)
Pre- 
antidopaminergic 
and post- 
antidopaminergic 
treatment group
(n=90)
Number of visits 4.4 (0.6)
4–6
4.3 (0.5)
4–6
Gender (m:f) 52:48 41:49
ISCED 3.8 (1.2)
1–6
3.5 (1.2)
2–6
Age 52.6 (12)
28–83
53 (11.3)
26–79
CAG repeat length 42.9 (4.9)
38–52
43.4 (2.6)
39–51
DBS 388 (78.2)
167.5–589
392.9 (66.1)
202.5–567
TFC score
Max score 13
10.1 (3.2)
0–13
9.2 (3.2)
0–13
Time since diagnosis
(years)
4.1 (4.2)
0–20
4 (4)
0–20
Motor score (UHDRS)
Max score 124
28.1 (18.18)
5–95
31.3 (15.4)
7–80
Total chorea score (UHDRS)
Max score 28
7.8 (4.9)
0–21
9.5* (5)
0–21
Irritability
(PBA)
Max score 32
1.8 (2.8)
0–13
4.3† (5.6)
0–24
Depression
(PBA)
Max score 48
2.7 (3.9)
0–18
4.2* (5.5)
0–23
Apathy
(PBA)
Max score 16
2 (3.7)
0–16
2.8 (4.1)
0–16
MMSE
Max score 30
27.5 (2.6)
17–30
26.3 (2.9)
16–30
Composite cognitive z- score 1.5 (5.4)
−11.2 to 15.8
1.7† (4.8)
19.2–11.3
ISCED, The International Standard Classification of Education; CAG, cytosine- adenine- guanine; MMSE, 
Mini- Mental State Examination.
*Indicates a significant difference (p<0.005) when compared with the control non- antidopaminergic 
medication group.
†Indicates a significant difference (p<0.001) when compared with the control non- antidopaminergic 
medication group.
DBS, disease burden score; PBA, problems behavioural assessment; TFC, total functional capacity; 
UHDRS, Unified Huntington Disease Rating Scale.
individuals were on average older, had been diagnosed with HD 
for longer and were at a more advanced disease stage than those 
not taking antidopaminergic medication (online supplementary 
table S1). After propensity score matching, there were no differ-
ences between the groups in terms of age, CAG repeat length, 
TFC score, time since diagnosis, educational level and DBS 
(p>0.05, see table 2). However, the group on antidopaminergic 
medication had significantly greater scores for both UHDRS 
total motor and total chorea scores, and for PBA depression, 
apathy and irritability scores (p<0.001 for all). Importantly, 
aside from the total motor score, the differences between groups 
were small (around a 1- point difference). However, increased 
motor and psychiatric impairments in this group are expected, 
since these patients were specifically prescribed this medication 
to treat these symptoms (with 67% being prescribed for motor 
impairments and 28% for psychiatric impairments, see online 
supplementary table S3). The antidopaminergic group also had 
a significantly lower composite total cognitive z- score than the 
non- antidopaminergic group (p=<0.001, see table 2), and a 
lower raw score in all of cognitive tasks except Trail making A 
(see online supplementary table S4), indicating worse perfor-
mance. It is, therefore, important to note that the group on anti-
dopaminergic medication appear to be at a similar disease stage 
but with having a more severe disease profile at baseline.
Next, we selected a separate group of patients to investigate 
whether the introduction of antidopaminergic medication led to 
changes in motor, cognitive or psychiatric decline. While this 
group also had a matched control group, the controls again had 
significantly less motor, psychiatric and cognitive impairment 
(see demographics table 3 and online supplementary table S5). 
Therefore, while the control group can provide an indication 
of the expected change in score over the 4- year time period 
in manifest HD patients, it comprises a somewhat clinically 
different group to those who start the medication.
Group 1 hd antidopaminergic takers (n= 466) and hd 
controls (non-antidopaminergic takers) (n= 466)
There was no difference in the annual change in UHDRS motor 
score between groups (F (1, 890)=8.359, p=0.215), with anti-
dopaminergic medication takers showing an average increase 
of 4.1 ± 6.8 points per year and controls showing an average 
increase of 3.5±7 points (see table 4 and figure 1A). When each 
of the individual measures of the UHDRS motor score were 
considered, the antidopaminergic medication group exhibited a 
greater annual increase in their Luria tristep score (p=0.002) 
and dysarthria (p=0.020) (data not shown), but a significantly 
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Table 4 Group 1. average annual mean change in score for motor, psychiatric and cognitive measures per group (SD in brackets)
Non- antidopaminergic
medication
takers
(n=466)
Antidopaminergic
medication
takers
(n=466) P value Cohen’s d
UHDRS total motor score 3.5
(6.8)
4.1
(7)
0.215 0.09
UHDRS total chorea score 0.4
(2.7)
−0.1*
(2.8)
0.004 0.18
Irritability
(PBA)
0.3
(3.6)
−0.4*
(3.1)
0.003 0.21
Depression
(PBA)
−0.2
(4.1)
−0.3
(5)
0.674 0.02
Apathy
(PBA)
0.3
(2.7)
0.5
(3.4)
0.391 0.07
Composite cognitive z- score 0.8
(3.5)
−0.8†
(4.8)
<0.001 0.4
TFC score −0.5
(1.4)
−1*
(1.4)
<0.001 0.35
UHDRS independence scale −2.5
(6)
−3.8*
(6.8)
0.004 0.2
P values are from a univariate analysis of variance (ANOVA) with age and CAG as covariates.
*Indicates a significant difference (p<0.005) when compared with the control non- antidopaminergic medication group.
†Indicates a significant difference (p<0.001) when compared with the control non- antidopaminergic medication group.
PBA, problems behavioural assessment; TFC, total functional capacity; UHDRS, Unified Huntington Disease Rating Scale.
smaller annual increase in chorea score when compared with 
those not on the treatment (0.4±2.8 vs −0.1±2.7 points, F (1, 
895)=8.674, p=000, table 4 and figure 1B).
Similarly, the antidopaminergic medication group displayed 
a significantly lower annual increase in the irritability score 
compared with non- takers (−0.4±3.6 points vs 0.3±3.1 points, 
F (1, 895)=8.674, p=0.003) (see table 4 and figure 1C). In 
contrast, there were no differences between groups for depres-
sion (F (1, 905)=0.178, p=0.674) or apathy (F (1, 912)=1.711, 
p=0.391) (see table 4). As this analysis included participants 
who scored zero for these measures, we repeated the analysis 
including only those prescribed the medication specifically for 
depression or apathy. There were still no differences in the rate 
of change between groups for either problem (data not shown).
We next assessed the effect of antidopaminergic medication 
on cognitive performance (see table 4 for the composite cogni-
tive z- score and online supplementary table S6 for the results of 
each individual cognitive task). HD patients taking antidopami-
nergic medication had a significantly lower z- score than non- 
takers (−0.8±4.8 vs 0.8±3.5, F (1, 902)=29.161, p<0.001) 
indicative of greater impairment (see figure 1D). In terms of 
the individual cognitive tasks, the antidopaminergic group 
exhibited a greater decline in all tasks (p<0.001), except Trail 
making A score (p=0.325). A multiple linear regression showed 
the degree of decline in composite cognitive z- score was signifi-
cantly predicted by group (antidopaminergic takers vs non- 
takers), but not by gender, age, CAG repeat length, DBS, TFC, 
time since diagnosis, ISCED or by motor or psychiatric scores (F 
(12,878)=3.439, p<0.001, R2=0.045) (see table 5).
Finally, the antidopaminergic medication group had 
significantly greater decreases in UHDRS TFC score (F (1, 
896)=32.993, p<0.001) and UHDRS independence score (F 
(1, 895)=8.482, p=0.004, see table 4), indicative of a greater 
annual loss in function and independence.
The earlier pattern of results was also found when propensity 
matching was not performed and the two groups were compared 
using a multivariate ANOVA with age, gender, CAG repeat 
length, DBS, TFC and time since diagnosis as the variables (see 
online supplementary table S2).
Group 2 Pre-HD and post-HD antidopaminergic takers (n= 90) and 
matched HD controls (non-antidopaminergic takers) (n= 108)
Next, we selected a separate group of antidopaminergic medi-
cation takers with at least two assessments prior to starting the 
medication and two assessments after starting the medication 
(see table 6 and figure 2A–D). Onset of the medication led to 
a reduction in the average annual increase in UHDRS motor 
score (from 5.7±11.2 points to 2.9±9.2 points), which did not 
reach significance (t (74)=1.178, p=0.079). This was because 
of a significantly reduced annual increase in UHDRS chorea 
score post- medication (1.1±4.7 points vs −0.5±5.5 points, t 
(89)=2.122, p=0.037), (see table 6 and figure 2B as well as a 
significant decrease in saccade initiation) (from a 0.6±1.5- point 
increase to a 0.03±1.7- point increase p=0.020). In contrast, 
all other measures of UHDRS motor score remained stable pre- 
medication and post- medication (data not shown).
By comparison, the matched control group displayed no signif-
icant changes in motor (t (101)=0.239, p=0.265) or chorea 
scores (t (98)=0.951, p=0.344). Thus, while the antidopami-
nergic group showed significantly greater increases in motor 
score than the control group pre- medication (F (1, 171)=4.392, 
p=0.038), they showed an equivalent rate of increase to controls 
post- medication (F (1, 169)=0.012, p=0.914), together with a 
significantly lower increase in chorea score (F (1, 183)=4.867, 
p=0.029).
There were, though, no differences found before or after 
onset of antidopaminergic medication in terms of depression (t 
(76)=0.665, p=0.508) or apathy (t (78)=0.853, p=0.00.396) 
(see table 6). Similarly, the matched control group showed no 
significant change in these measures across the same time inter-
vals. However, for irritability, while both groups had similar 
rates of decline during time interval 1, the group starting anti-
dopaminergic medication displayed a strong trend for a reduced 
rate of increase in post- medication (t (78)=1.872, p=0.065), 
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Figure 1 graphs showing average annual change in UhDrs total motor score, PBa irritability and composite cognitive score per group. group 1. (a) 
There is no difference in the annual increase in UhDrs total motor score between hD antidopaminergic medication takers and hD non- antidopaminergic 
medication takers. (B) hD patients taking antidopaminergic medication had a significantly reduced increase in chorea score compared with hD controls not 
taking antidopaminergic medication. (c) antidopaminergic medication takers had a significantly smaller increase in reported irritability on the PBa compared 
with patients not on Da altering medications.(D) hD antidopaminergic medication takers had a statistically faster rate of cognitive decline than hD patients 
not taking these drugs. groups were compared using univariate analysis with age, cag and gender as covariates. Mean and se of the mean are shown. 
***p<0.001. n=466 per group. Da, dopamine; hD, huntington’s disease; PBa, problems behavioural assessment; UhDrs, Unified huntington Disease 
rating scale.
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Table 5 Group 1. Multivariate regression analysis showing factors 
associated with change in composite cognitive score
Predictor variable
Change in total cognitive z- score
b coefficient P value
Constant −1.689 0.781
Group (antidopaminergic takers vs non- 
antidopaminergic takers)
−1.244 <0.001
Age 0.046 0.071
Gender 0.083 0.493
CAG repeat length 0.094 0.430
DBS −0.008 0.008
TFC −0.039 0.586
Time since diagnosis 0.020 0.619
UHDRS total motor score −0.003 0.813
Depression (PBA) −0.012 0.659
Irritability (PBA) −0.059 0.087
Apathy (PBA) 0.030 0.445
ISCED −0.155 0.183
ISCED, The International Standard Classification of Education; CAG, cytosine- 
adenine- guanine.
DBS, disease burden score; PBS, problems behavioural assessment; TFC, total 
functional capacity; UHDRS, Unified Huntington Disease Rating Scale.
Table 6 Group 2. Average annual mean change in score for pre- antidopaminergic and post- antidopaminergic takers and matched controls (SD in 
brackets)
Control group
(time 1)
(n=103)
Control group
(time 2)
(n=103) P value Cohen’s d
Pre- antidopaminergic 
medication
(time 1)
(n=90)
Post- 
antidopaminergic
Medication
(time 2)
(n=90) P value Cohen’s d
UHDRS total motor score 2.4
(7.9)
2.7
(7.6)
0.819 0.04 5.7
(11.2)
2.9
(9.2)
0.079 0.27
UHDRS total chorea score 0.4
(4.5)
1
(4.2)
0.344 0.14 1.1
(4.7)
−0.5*
(5.5)
0.036 0.31
UHDRS saccade initiation 0.4
(1.4)
0.1
(1.4)
0.100 0.21 0.6
(1.5)
0.03*
(1.7)
0.020 0.35
Irritability
(PBA)
0.4
(4)
0.6
(3.4)
0.745 0.05 0.1
(6.2)
−1.8
(6.2)
0.065 0.31
Depression
(PBA)
−0.1
(4.1)
−0.1
(4.5)
0.962 0 0.8
(6.2)
−0.2
(6.7)
0.508 0.2
Apathy
(PBA)
0.02
(2.9)
0.3
(3.3)
0.474 0.09 0.3
(4)
0.9
(4.9)
0.396 0.13
Total composite cognitive z- 
score
0.4
(3.9)
−0.3
(4)
0.199 0.18 0.8
(3.4)
−0.7***
(3.4)
0.001 0.44
TFC score −0.6
(1.3)
−0.4
(1.6)
0.483 0.13 −0.9
(1.8)
−1
(1.6)
0.664 0.05
UHDRS independence scale −3.1
(7.6)
−1.8
(9.5)
0.3 0.15 −5.2
(9.5)
−3.6
(7.3)
0.183 0.18
P values are from paired t- tests.
*Indicates a significant difference (p<0.005) when compared with the control non- antidopaminergic medication group.
†Indicates a significant difference (p<0.001) when compared with the control non- antidopaminergic medication group.
PBA, problems behavioural assessment; TFC, total functional capacity; UHDRS, Unified Huntington Disease Rating Scale.
which meant that they had a significantly lower average increase 
than the matched control group during time interval 2 (F (1, 
175)=10.061, p=0.002) (see figure 2C).
Those prescribed antidopaminergic medication also showed 
a significant decrease in cognitive z- score post- medication, with 
a z- score of 0.8±3.4 before medication and −0.7±3.4, post- 
medication (t (76)=3.332, p=0.001) (see table 6 and figure 2D). 
This was driven by a greater decline in the verbal fluency, Stroop 
word and interference and the Trail making B tasks (p<0.05, see 
online supplementary table S7), whereas there were no signif-
icant differences for SDMT, Stroop naming or Trail making A 
pre- medication and post- medication (p>0.05). In comparison, 
the matched controls displayed no change in z- score or in any 
individual cognitive task over the time intervals (t (92)=1.293, 
p=0.199).
Finally, for the antidopaminergic medication group, there 
were no differences in annual change in score pre- medication 
or post- medication for TFC (t (80)=0.435, p=0.664) or inde-
pendence scales (t (80)=1.342, p=0.184, table 6), suggesting 
that the medication did not directly impact on how the disease 
affects functional capacity. Similarly, the matched control group 
didn’t show any significant changes in annual progression of 
these measures at different time points (see table 6).
dIsCussION
This study interrogated the Enroll- HD database to investigate 
effects of antidopaminergic treatments on motor, cognitive and 
psychiatric function over a 3- year period.
effect of antidopaminergic medication on function and 
independence
Those on antidopaminergic medication showed a greater annual 
decline in TFC and independence scores than those who were 
not. However, seeing as there were no differences in the rate of 
change in these measures following the onset of the antidopami-
nergic medication, this is unlikely to be a result of the dopami-
nergic medication itself, and may instead reflect the fact that this 
group had a more severe disease profile at baseline.
effect of antidopaminergic medication on motor features
The annual increase in UHDRS chorea score over a 3- year period 
was, not surprisingly, significantly lower in HD patients taking 
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Figure 2 graphs showing average annual change in UhDrs total motor score, PBa irritability and composite cognitive score per group. group 2. 
(a) hD patients who had a period of assessment before being prescribed antidopaminergic medications did not show a significant difference in annual 
change in motor score pre- antidopaminergic and post- antidopaminergic medication introduction. Matched controls also did not show a significant 
difference across the two time intervals. (B) hD patients showed a diminished increase in chorea score in the period after they were prescribed the 
antidopaminergic medication. in contrast, matched controls did not show significant changes in chorea score between the two time intervals. (c) The 
onset of antidopaminergic medication did not have a significant effect on PBa irritability scores. Matched controls also did not display significant changes 
in irritability score. (D) hD patients who began antidopaminergic medication showed a significantly faster rate of cognitive decline in the period after 
medication introduction. in contrast, matched controls did not show any change in cognitive score. a paired t- test compared scores of time interval 1 (pre- 
antidopaminergic medication) with time interval 2 (post- antidopaminergic medication). a univariate anOVa compared scores of each group during each 
time interval with age, cag and gender as covariates. p<0.05. n=81 pairs. hD, huntington’s disease; PBa, problems behavioural assessment; UhDrs, 
Unified huntington Disease rating scale.
antidopaminergic medication compared with HD patients who 
were not. Furthermore, HD patients beginning antidopaminergic 
medication part way through the study showed a significant 
1.6- point reduction in chorea score on the UHDRS after starting 
the medication. This result is to be anticipated especially given the 
results of two clinical trials assessing tetrabenazine (TETRA- HD, 
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Huntington Study Group22) and its modified form, deutetra-
benazine (FIRST- HD, Frank et al23), which, respectively, showed 
a 3.5- point and 2.5- point reduction in UHDRS chorea score, 
after 12 weeks of treatment. The smaller reduction obtained in 
this study may be explained by differences between the studies, 
eg differences in duration of treatment, sample population and 
most importantly our study looked at a number of different anti-
dopaminergic medications (see table 1).
In regard to the DA antagonists which are commonly 
prescribed off- label in HD, there have been a few small open- 
label studies which showed significant improvements in psychi-
atric measures but inconsistent motor effects, with some studies 
showing improvement,24 25 some stabilisation26 and some no 
change.27 One open label study with olanzapine showed a 1.6- 
point reduction in UHDRS chorea score in 11 HD patients after 
6 months,28 which is in line with our results. Our analysis is the 
first to assess the longitudinal effects of DA antagonists in a large 
sample of participants and provides evidence in support of their 
beneficial effect for the treatment of chorea in HD.
Interestingly, we also found that antidopaminergic medica-
tion was associated with an improvement in saccade initiation 
deficits. It is well established that the basal ganglia controls the 
initiation of eye movements via inhibition of the superior collic-
ulus.29 However, evidence for a role of DA in this process in 
humans is lacking, although a correlation between the degree of 
striatal DA transporter binding and the severity saccadic errors 
has been reported in patients with Parkinson’s disease.30 Impor-
tantly, this study suggests that the onset of antidopaminergic 
medication may improve saccade initiation in HD, but further 
work is needed to explore this.
A recent retrospective analysis of the EHDN (European 
Huntington's Disease Network) REGISTRY study showed that in 
contrast to our results, antidopaminergic medication takers had 
a greater annual increase in UHDRS total motor score (including 
oculomotor dysfunction), compared with a control group.31 The 
authors also showed that the annualised progression of chorea 
and dystonia did not differ between the groups. Crucially, the 
two groups weren’t matched on demographic or clinical vari-
ables, meaning that the antidopaminergic group were older, 
had a longer disease duration and also a higher disease burden 
score, and therefore a faster disease progression may have been 
expected. The fact that chorea and dystonia did not differ 
between the two groups, even in these circumstances, suggests 
that the antidopaminergic medication may have been of some 
benefit to these features of the disease. Our study suggests that 
if the groups were better matched, improvements in chorea and 
saccade initiation may have become apparent.
effect of antidopaminergic medication on psychiatric features
HD patients on antidopaminergic medication showed a reduced 
annual increase in irritability scores compared with HD patients 
who were not, suggesting this medication may be beneficial in 
treating irritability in HD. These results support case studies 
highlighting the efficiency of olanzapine,28 32 33 risperidone25 and 
quetiapine26 in treating this aspect of HD. However, we found 
that these drugs did not appear to impact on annual changes 
in apathy or depression scores, suggesting that while the medi-
cation is not improving apathy it is also not making it worse. 
Theoretically, reducing levels of DA could lead patients to expe-
rience a reduction in their motivation and given that apathy is a 
prominent feature of HD, these drugs might have been predicted 
to make this aspect of their symptomatology worse. This was not 
seen and is in line with a recent trial showing that bupropion was 
ineffective for treating this symptom.34 However, randomised 
controlled trials, which include detailed scales to assess these 
conditions, are needed to more thoroughly explore the role of 
DA in depression and apathy in HD.
effect of antidopaminergic medication on cognitive features
Assessment of the effects of antidopaminergic medication on the 
cognitive tasks performed in Enroll- HD is of particular impor-
tance given the impact these problems have on quality of life. We 
found that HD patients on antidopaminergic medication had a 
more rapid annual cognitive decline than HD patients who were 
not. Studies of cognition in healthy individuals have also shown 
that DA antagonists can be detrimental to cognition.35–37 Exactly 
why this should be the case is unclear, but it is known that DA 
modulates cognition in an inverted U function whereby both 
excessive and insufficient DA is detrimental to certain cognitive 
processes in healthy individuals16 and thus it may be that these 
drugs in HD move patients away from their optimal DA level.
Importantly, as this is an observational study, causality cannot 
be established, and it is possible that the differences viewed 
between the groups were driven by other unknown factors unre-
lated to DA or the other variables we controlled for. Furthermore, 
there was innate bias in the data set as those taking antidopami-
nergic had a more severe disease phenotype and therefore may 
represent a subgroup of HD with faster HD- related cognitive 
deterioration, irrespective of medication, as we have reported 
previously.38 39
We sought to try and investigate this by looking at the speed of 
cognitive decline before and after antidopaminergic drugs were 
started. We found again that cognition worsened significantly 
in HD patients in the period subsequent to taking antidopami-
nergic medication for four of the seven cognitive tasks and this 
was not observed in the control group. Interestingly, two of these 
tasks (Trail making B and Stroop interference), require flexibility 
and set- shifting, processes known to be dependent on dopamine. 
However, while the tasks included in Enroll- HD are useful tools 
to obtain a basic indication of cognitive function, the battery was 
not designed specifically to be sensitive to DA- dependent cogni-
tive processes. Future research should study the effects of DA 
antagonism on cognition in HD in a more controlled manner, 
using tasks specific to the function of DA.
This study has a number of other limitations outside of the 
bias in terms of patient selection to the database. For example, 
scores on a particular day could be affected by a number of 
factors, such as tiredness, mood or other medications. Further-
more, some of the DA antagonists included in the study do not 
selectively act on DA receptors but also block other receptors, eg 
serotonin receptors. Since manipulations of serotonin have been 
shown to induce changes in cognitive functioning,40 it cannot 
be ruled out that the results of this study were influenced by 
changes in levels of serotonin in addition to dopamine.
Despite these drawbacks, this is the first study to assess the 
longitudinal effects of antidopaminergic medication on each of 
the major clinical aspects of HD. The results suggest that the 
medication is beneficial in treating chorea and irritability but 
may not influence apathy and depression. Antidopaminergic 
medication also appears to be associated with worsening cogni-
tion, which has important clinical implications since patients 
often report cognitive impairments to be more disruptive to 
daily life than motor disturbances. However, more controlled 
prospective studies are needed to fully elucidate the causative 
role of DA in cognitive impairments in HD and/or whether there 
are subtypes of disease that should be treated differently.
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